

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )				
/E.A./	BA	WO-96/40108-A1	12-19-1996	Univ Washington et al.		
/E.A./	BB	WO-02/26226-A1	04-04-2002	Chongqing Kincare Medicinal De et al.		See Abstract

Examiner Signature	/Ernst Arnold/	Date Considered	09/23/2010
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For European patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08b (07-09)

Approved for use through 07/31/2012. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>				Application Number	10/587,277-Conf. #4870
				Filing Date	July 25, 2006
				First Named Inventor	LI Guogiao
				Art Unit	1616
				Examiner Name	E. V. Arnold
Sheet	2	of	2	Attorney Docket Number	13796-00002-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/E.A./	CA	DENIS, M.B. et al., "Efficacy and Safety of Dihydroartemisinin-Piperaquine (Artekin) in Cambodian Children and Adults with Uncomplicated Falciparum Malaria." <i>Clin. Inf. Dis.</i> <b>35(12)</b> , 1469-1476 (2002).	
	CB	HUANG, J.R. et al., "A study of artemether combined with primaquine in the treatment of falciparum malaria." <i>DATABASE MEDLINE (Online)</i> , U.S. National Library of Medicine, Bethesda, MD, US, 2001, Database Accession No. NLM12572052 (abstract only).	
	CC	CHAWIRA, N. et al., "The effect of artemisinin combined with standard antimalarials against chloroquine-sensitive and chloroquine-resistant strains of <i>Plasmodium falciparum</i> in vitro." <i>Journal of Tropical Medicine and Hygiene</i> <b>90</b> , 1-8 (1987).	
	CD	GIAO, P.T. et al., "CV8, a new combination of dihydroartemisinin, piperaquien, trimethoprim and primaquine, compared with atovaquone-proguanil against falciparum malaria in Vietnam." <i>Tropical Medicine and International Health</i> <b>9(1)</b> , 109-116 (2004).	
	CE	"Antimalarial Drug Combination Therapy: Report of a WHO Technical Consultation." World Health Organization, 2001, 1-30.	
	CF	JAEGER, A. et al., "Clinical features and management of poisoning due to antimalarial drugs." <i>Med. Toxicol. Adverse Drug Exp.</i> 1987 Jul-Aug; <b>2(4)</b> : 242-73.	
	CG	SRIVASTAVA, P. et al., "Glutathione S transferase activity in malarial parasites." <i>Tropical Medicine and International Health</i> <b>4(4)</b> , January 5, 2002, 251-254.	
	CH	SONG, J. et al., "Clinical Observation of Dihydroartemisinin and Piperaquine in Treating Falciparum Malaria without Complication." <i>National Medical Journal of China</i> <b>83(12)</b> , 6/25/03, 1099-1100 (original article plus English translation).	x

Examiner Signature	/Ernst Arnold/	Date Considered	09/23/2010
--------------------	----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.